Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin ManifestationsBusiness Wire • 04/30/26
Will Merck KGaA (MKKGY) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 02/03/26
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson's Disease and Related DisordersBusiness Wire • 11/20/25